The oncogenic role of c-MYB is not limited to ovarian cancer and has been reported in hematological malignancies as well as several solid tumors9–13, Despite such wealth of information regarding the oncogenic potential of c-MYB, its role in cisplatin resistance was not known prior to this report9. This evidence concerns the gene MYB and ovarian carcinoma.